1887

Abstract

Summary

The reported serological relatedness between the major glycoproteins of human immunodeficiency virus (HIV gp120) and equine infectious anaemia virus (EIAV gp90) was examined using purified antigens in radioimmunoprecipitation (RIP), radioimmunoassay (RIA) and immunoblot assays with reference serum from acquired immunodeficiency syndrome (AIDS) patients, an anti-gp120 goat serum and EIAV-infected horse serum. To assess the contributions of glycoprotein oligosaccharide and peptide components to any observed reactivities, antigens treated with endoglycosidase F to remove carbohydrate were assayed in parallel with the intact glycoprotein. The results of the experiments indicated that the reactivity observed for each antigen was dependent on the immunoassay employed. The RIP and RIA analyses demonstrated that HIV gp120 is equally reactive with the AIDS patient serum, the goat anti-gp120 serum and the EIAV-infected horse serum, whereas the EIAV gp90 reacted only with the horse serum. In immunoblot assays, the HIV gp120 reacted with AIDS patient serum, but not with the EIAV-infected horse serum. Deglycosylation of the HIV gp120 evidently increased its reactivity with the AIDS patient serum, had no significant effect on its reactivity with the goat antiserum, and essentially abolished its reactivity with the EIAV reference serum. Thus, it appears that the serological cross-reactivity observed between HIV gp120 and sera from EIAV-infected horses can be attributed to the oligosaccharide rather than the peptide components of the viral glycoprotein. These studies also emphasize the necessity of employing several assay procedures in assessing lentivirus antigenicity.

Keyword(s): cross-reactivity , EIAV , glycoproteins and HIV
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-69-7-1711
1988-07-01
2024-12-13
Loading full text...

Full text loading...

/deliver/fulltext/jgv/69/7/JV0690071711.html?itemId=/content/journal/jgv/10.1099/0022-1317-69-7-1711&mimeType=html&fmt=ahah

References

  1. ALLAN J. S., COLIGAN J. E., BARIN F., MCLANE M. F., SODROSKI J. G., ROSEN C. A., HASELTINE W. A., LEE T. H., ESSEX M. 1985; Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228:1091–1094
    [Google Scholar]
  2. ELDER J. H., ALEXANDER S. 1982; Endo-β-N-acetylglucosaminidase F: endoglycosidase from Flavobacterium meningosepticum that cleaves both high-mannose and complex glycoproteins. Proceedings of the National Academy of Sciences, U.S.A 79:4540–4544
    [Google Scholar]
  3. GONDA M. A., BRAUN M. J., CARTER S. G., KOST T. A., BESS J. W. JR, ARTHUR L. O., VAN DER MAATEN M. J. 1987; Characterization and molecular cloning of a bovine lentivirus related to human immunodeficiency virus. Nature, London 330:388–390
    [Google Scholar]
  4. GOUDSMIT J., HOUWERS D. J., SMIT L., NAUTA I. M. 1986; LAV/HTLV-III gag gene product p24 shares antigenic determinants with equine infectious anaemia virus but not with visna virus or caprine arthritis-encephalitis virus. Intervirology 26:169–173
    [Google Scholar]
  5. MONTAGNIER L., DAUGUET C, GRUEST I., NUGREYRE M. T., REY F., BARRE-SINOUSSI F., CHERMANN J. C. 1984; A new type of retrovirus isolated from patients presenting with lymphadenopathy and AIDS: structural and antigenic relationship with EIAV. Annales de l’Institut Pasteur/Virologie 135E:119–134
    [Google Scholar]
  6. MONTELARO R. C, PAREKH B. S., ORREGO A., ISSEL C. J. 1984a; Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus. Journal of Biological Chemistry 259:10539–10544
    [Google Scholar]
  7. MONTELARO R. C, WEST M. D., ISSEL C. J. 1984b; Antigenic reactivity of the major glycoprotein of equine infectious anemia virus, a retrovirus. Virology 136:368–374
    [Google Scholar]
  8. MURPHEY-CORB M., MARTIN L. N, RANGAN S. R. S., BASKIN G. B., GORMUS B. J., WOLF R. H., ANDES W. A., WEST M., MONTELARO R. C. 1986; Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys. Nature, London 321:435–437
    [Google Scholar]
  9. PAREKH B. S., ISSEL C. J., MONTELARO R. C. 1980; Equine infectious anemia virus, a putative lentivirus, contains polypeptides analogous to prototype-C oncornaviruses. Virology 107:520–525
    [Google Scholar]
  10. PEDERSEN N. C, HO E. W., BROWN M. L., YAMAMOTO J. K. 1987; Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 235:790–793
    [Google Scholar]
  11. ROBEY W. G., ARTHUR L. O., MATTHEWS T. J., LANGLOIS A., COPELAND T. D., OROSZLAN S., BOLOGNESI D. P., GILDEN R. V., FISCHINGER P. J. 1986; Prospect for prevention of human T-cell lymphotropic virus (HTLV-III) infection: purified 120000 dalton envelope glycoprotein induces neutralizing antibody. Proceedings of the National Academy of Sciences, U.S.A 83:7023–7027
    [Google Scholar]
  12. RUSHLOW K., OLSEN K., STIEGLER G., PAYNE S. L., MONTELARO R. C., ISSEL C. J. 1986; Lentivirus genomic organization: the complete nucleotide sequence of the env gene region of equine infectious anemia virus. Virology 155:309–321
    [Google Scholar]
  13. SARNGADHARAN M. G., BRUCH L., POPOVIC M., GALLO R. C. 1985; Immunological properties of the gag protein p24 of the acquired immunodeficiency syndrome retrovirus (human T-cell leukemia virus type III). Proceedings of the National Academy of Sciences, U.S.A 82:3481–3484
    [Google Scholar]
  14. SCHNEIDER J., HUNSMANN G. 1978; Surface expression of murine leukemia virus structural polypeptides on host cells and the virion. International Journal of Cancer 22:204–213
    [Google Scholar]
  15. SCHNEIDER J., KAADEN O., COPELAND T. D., OROSZLAN S., HUNSMANN G. 1986; Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp 120 of human immunodeficiency virus. Journal of General Virology 67:2533–2538
    [Google Scholar]
/content/journal/jgv/10.1099/0022-1317-69-7-1711
Loading
/content/journal/jgv/10.1099/0022-1317-69-7-1711
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error